CV Therapeutics (CVTX) over all option implied volatility at 123 into Ranexa Data
More News related to CVTX
- Spring Brings 'Green Shoots' For Stocks
- Notable Mergers and Acquisitions of the Day 3/16: BCS, CVTX, BAM
- Astellas Pharma Terminates $16/Sh Offer for CV Therapeutics (CVTX), Clearing Way For Gilead
- Top 10 News Items 3/9-3/13: Stock Stage 4-Day Win Streak; Bank CEOs Make Upbeat Comments (C, JPM, BAC); GE (GE) Gets Rating Cut
- Unusual 11 Mid-Day Movers 3/12: BRNC, CVTX, SEH, MW Higher; MTG, PDII, NP, STLD Lower
More News related to Analyst Comments
- Goldman Sachs Added Cytec Industries (CYT) to their Conviction Sell List
- FBR Capital Recommends An IPO or Spin Off at Chesapeake Energy (CHK)
- Canaccord Adams Maintains a 'Buy' on Silver Wheaton (SLW); Raises Price Target
- Citi Boosts Target on McDonald's (MCD) to $64, Maintains Hold
- Canaccord Adams Reiterates a 'Buy' on Veeco Instruments (VECO); Raises PT & Estimates
CV Therapeutics (Nasdaq: CVTX) : CVTX is recently trading down $3.11 to $9.19 in pre-open trading. COWN says "Top-line results from the MERLIN trial reported established Ranexa's safety, but fell short of meeting the trial's primary efficacy endpoint in ACS (acute coronary syndrome). Ranexa's clean safety profile should enable a first-line label for chronic angina, but the commercial benefit of an expanded claim in a competitive marketplace is difficult to quantify. CVTX over all option implied volatility of 123 was above its 6-month average of 96 according to Track Data. Paul Foster
Related Categories
Analyst CommentsOptions
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
